Overview

• US biopharmaceutical firm's Q1 adjusted EPS met analyst expectations

• Q1 net income and operating income missed analyst estimates

• Company ended Q1 with $51.3 mln in cash and investments, runway projected through 2027

Outlook

• Company expects R&D expenses to moderately increase as clinical programs advance

• Company anticipates current cash and investments will fund operations through 2027

• DiaMedica expects G&A expenses to remain relatively consistent in future periods

Result Drivers

• R&D EXPENSES - Higher research and development expenses driven by continuation and global expansion of ReMEDy2 clinical trial, expansion of clinical team, and additional reproductive toxicity testing for PE program

• MANUFACTURING COST REDUCTIONS - Net cost reductions in manufacturing development activity partially offset expense increases

• TRIAL ENROLLMENT PROGRESS - ReMEDy2 stroke trial surpassed 70% of required enrollment, with interim analysis planned for 4Q 2026

Company press release: ID:nBwbZ1CPwa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 EPS	Meet	-$0.19	-$0.19 (4 Analysts)
Q1 Net Income	Miss	-$10.04 mln	-$9.53 mln (3 Analysts)
Q1 Operating Income	Miss	-$10.48 mln	-$9.86 mln (3 Analysts)
Q1 Cash & Investments		$51.30 mln
Q1 Pretax Profit		-$10.04 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for DiaMedica Therapeutics Inc is $13.00, about 108% above its May 5 closing price of $6.25

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.